Uso racional de medicamentos: temas selecionados, 2012.

Referências
1. GUS, M.; FUCHS, F. D. Antitrombóticos.
In: FUCHS, F.D.; WANNMACHER, L. ( Ed.)
Farmacologia clínica: fundamentos da
terapêutica racional. 4. ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 891-910.
2. BANE, M. C.; WYSOKINSKI, R. D. Pathophysiology
of arterial thrombosis. In: MURPHY, J. D.; LLOYD,
M. A. (Org). Mayo Clinic Cardiology. 3. ed. Florida:
Taylor & Francis Group, 2007. p. 625-634.
3. SCURR, J.H. et al. Frequency and prevention
of symptomless deep-vein thrombosis in longhaul
flights: a randomised trial. Lancet, London,
v. 357, n. 9267, p. 1485-1489, May 2001.
4. BRASIL. Ministério da Saúde. Secretaria de
Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e
Insumos Estratégicos. Relação nacional de
medicamentos essenciais: Rename 2010. 7.
ed. Brasília, DF, 2010. 250 p.
5. ANTITHROMBOTIC TRIALISTS’ (ATT)
COLLABORATION. Aspirin in the primary and
secondary prevention of vascular disease:
collaborative meta-analysis of individual participant
data from randomised trials. Lancet, London, v.
373, n. 9678, p. 1849-1860, May 2009.
6. POLANCZYK, C. A.; FURTADO, M. V.;
FUCHS, F. D. Fármacos usados em cardiopatia
isquêmica. In: FUCHS, F. D.; WANNMACHER,
L. (Ed.). Farmacologia clínica: fundamentos
da terapêutica racional. 4. ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 818-842.
7. STAVRAKIS, S. et al. Low-dose aspirin for
primary prevention of cardiovascular events in
patients with diabetes: a meta-analysis. The
American Journal of the Medical Sciences,
Philadelphia, v. 341, n. 1, p. 1-9, Jan. 2011.
8. OWEN, A. Antithrombotic treatment for the
primary prevention of stroke in patients with
non valvular atrial fibrillation: a reappraisal
of the evidence and network meta-analysis.
International Journal of Cardiology,
Amsterdam, v. 142, n. 3, p. 218-223, Jan. 2010.
9. GOLDSTEIN, L. B. et al. American Heart
Association; American Stroke Association Stroke
Council. Primary prevention of ischemic stroke:
a guideline from the American Heart Association/
American Stroke Association Stroke Council:
cosponsored by the Atherosclerotic Peripheral
Uso Racional de Medicamentos: temas selecionados
153
Vascular Disease Interdisciplinary Working Group;
Cardiovascular Nursing Council; Clinical Cardiology
Council; Nutrition, Physical Activity, and Metabolism
Council; and the Quality of Care and Outcomes
Research Interdisciplinary Working Group. Circulation,
Dallas, v. 113, n. 24, p. e873-923, Jun. 2006.
10. BOZIC, K.J. et al. Does aspirin have a role in
venous thromboembolism prophylaxis in total knee
arthroplasty patients? The Journal of Arthroplasty,
New York, v. 25, n. 7, p. 1053-1060, Aug. 2010.
11. LIÈVRE, M.; CUCHERAT, M. Aspirin in
the secondary prevention of cardiovascular
disease: an update of the APTC meta-analysis.
Fundamental & Clinical Pharmacology, Paris,
v. 24, n. 3, p. 385-391, Jun. 2010.
12. ANTITHROMBOTIC TRIALISTS’
COLLABORATION. Collaborative meta-analysis
of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and
stroke in high risk patients. BMJ, London, v. 324,
n. 7330, p. 71-86, Jan. 2002.
13. SUDLOW, C. L. M. et al. Thienopyridine
derivatives versus aspirin for preventing stroke and
other serious vascular events in high vascular risk
patient. Cochrane Database Syst Rev, Oxford,
Issue 04, Oct. 2009. Art. No. CD001246.
14. YUSUF, S. et al. Effects of clopidogrel in
addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. The
New England Journal of Medicine, Boston, v.
345, n. 7, p. 494-502, Aug. 2001.
15. MEHTA, S. R. et al. Effects of pretreatment with
clopidogrel and aspirin followed by long-term therapy
in patients undergoing percutaneous coronary
intervention: the PCI-CURE study. Lancet, London,
v. 358, n. 9281, p. 527-533, Aug. 2001.
16. SQUIZZATO, A. et al. Clopidogrel plus aspirin
versus aspirin alone for preventing cardiovascular
disease. Cochrane Database Syst Rev, Oxford,
Issue 01, Jan. 2011 CD005158.
17. DIENER, H. C. et al Effects of aspirin plus
extended-release dipyridamole versus clopidogrel and
telmisartan on disability and cognitive function after
recurrent stroke in patients with ischaemic stroke in the
Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial: a double-blind, active and
placebo-controlled study. Lancet Neurology, London,
v. 7, n. 10, p. 875-884, Oct. 2008.